Replimune Group 과거 순이익 실적
과거 기준 점검 0/6
Replimune Group의 수입은 연평균 -25.5%의 비율로 감소해 온 반면, Biotechs 산업의 수입은 연간 30.2% 증가했습니다.
핵심 정보
-25.51%
순이익 성장률
-12.97%
주당순이익(EPS) 성장률
| Biotechs 산업 성장률 | 17.04% |
| 매출 성장률 | n/a |
| 자기자본이익률 | -149.55% |
| 순이익률 | n/a |
| 최근 순이익 업데이트 | 31 Dec 2025 |
최근 과거 실적 업데이트
Recent updates
Seeking Alpha • Apr 10
Replimune: Second CRL May Have Sealed RP1's Fate - It's Hard To See Positives
Summary Replimune Group, Inc. suffered a second FDA rejection for RP1 in anti-PD-1 failed melanoma, causing a sharp stock decline and casting doubt on its near-term prospects. The FDA apparently cited inadequate evidence of effectiveness and trial design flaws, finding the IGNYTE study too heterogeneous and the confirmatory study insufficient. REPL’s cash runway may not extend beyond 12 months, and the company may need to restructure or reprioritize resources, with RP2 in metastatic uveal melanoma as a possible focus. Given persistent regulatory hurdles and uncertain funding, this does not appear to be a "buy the dip" opportunity for REPL. Read the full article on Seeking Alpha분석 기사 • Feb 08
Is Replimune Group (NASDAQ:REPL) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • Aug 01
Is Replimune Group (NASDAQ:REPL) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Seeking Alpha • Apr 28
Replimune: Scope Goes Beyond That Of RP1 Oncolytic Targeting For Melanoma
Summary Replimune Group, Inc.'s BLA of RP1 + OPDIVO in advanced melanoma received an FDA Priority Review, with a PDUFA date set for July 22, 2025. RP2, adding an anti-CTLA-4 component, is being tested in metastatic uveal melanoma and 2nd-line metastatic hepatocellular carcinoma patients. Financially, Replimune has $536.5 million in cash, but REPL will likely need additional funding within the next 12 months. The global liver cancer drugs market is expected to reach $14.9 billion by 2031. Read the full article on Seeking Alpha분석 기사 • Apr 11
Is Replimune Group (NASDAQ:REPL) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Feb 12
Replimune: A Misunderstood Contender In Oncolytics
Summary Replimune Group's solid cash position and strategic focus on niche oncology markets position it for potential success, despite market volatility and past trial setbacks. The company's RP1 and RP2 platforms target unmet needs in melanoma and other cancers, with promising data and regulatory momentum supporting their potential. The FDA's Priority Review and Breakthrough Therapy designations for RP1 underscore its potential to reshape second-line melanoma treatment and expedite market entry. Despite skepticism about oncolytic viruses, Replimune's approach and collaborations with big pharma could yield significant commercial opportunities if clinical data remains strong. Read the full article on Seeking AlphaSeeking Alpha • Nov 29
Replimune: RPL1 BLA Submission Under AA Pathway Makes It A Must Watch
Summary Replimune has submitted its BLA of RP1 + Opdivo for the treatment of advanced melanoma patients previously treated with an anti-PD1 containing regimen. The phase 3 confirmatory IGNYTE-3 study is underway to prove yet again that RP1 + Opdivo is able to help these patients with advanced melanoma and to keep the drug marketed. The global melanoma therapeutics market size is projected to reach $17.93 billion by 2034. RP2 is another drug in the company's pipeline which is being developed other than target metastatic uveal melanoma and Hepatocellular Carcinoma patients. Read the full article on Seeking Alpha분석 기사 • Nov 23
Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Seeking Alpha • Sep 03
Replimune: Strong Data In A Highly Differentiated Space
Summary Replimune's RP1, an oncolytic immuno-gene therapy, shows promise with a 31.4% ORR in phase 2 trials for post PD-1 melanoma and non-melanoma skin cancers. RP2, adding an anti-CTLA-4 component to RP1, demonstrated a 29.4% ORR in phase 1 trials, with durable responses in difficult-to-treat tumors. Despite competitive challenges and a failed CSCC trial, Replimune's cash runway supports its accelerated approval and phase 3 trials, making it an attractive investment. RP1 and RP2 together could be a game-changer, offering a compelling opportunity at current low stock prices. Read the full article on Seeking Alpha분석 기사 • Aug 16
Is Replimune Group (NASDAQ:REPL) Using Debt Sensibly?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Seeking Alpha • May 22
Replimune: Continuing To Justify The Bear Thesis (For Now)
Summary Replimune Group, Inc.'s stock has fallen 35% in 2024, and an inflection point is not expected yet. The company is working on RP1, an oncolytic virus therapy, and has shared positive results from their ARTACUS trial. Replimune plans to submit a BLA for RP1 approval in melanoma, but this is far from guaranteed, especially in 2024. Read the full article on Seeking Alpha분석 기사 • Feb 06
Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Seeking Alpha • Jan 23
Replimune: The Fall Is Justified, As Virus Therapy Fails Again In Cancer
Summary Replimune Group is developing virus-based treatments for solid tumors, particularly skin cancer. The company's RP1 treatment did not show significant improvement in response rates compared to standard care in a phase 1/2 study, though there is a signal of something buried therein. Replimune plans to initiate a confirmatory study for RP1 in melanoma patients and is also developing RP2 for uveal melanoma. Read the full article on Seeking Alpha분석 기사 • Dec 25
Calculating The Intrinsic Value Of Replimune Group, Inc. (NASDAQ:REPL)
Key Insights The projected fair value for Replimune Group is US$9.64 based on 2 Stage Free Cash Flow to Equity Current...분석 기사 • Jul 13
Is Replimune Group (NASDAQ:REPL) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • Apr 05
Is Replimune Group (NASDAQ:REPL) Using Debt In A Risky Way?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...분석 기사 • Jan 06
A Look At The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)
Key Insights Replimune Group's estimated fair value is US$25.6 based on 2 Stage Free Cash Flow to Equity Current share...Seeking Alpha • Oct 07
Replimune secures $200M term loan
Replimune Group (NASDAQ:REPL) has secured a $200M non-dilutive term loan facility from Hercules Capital. The loan facility consists of up to six tranches, five of which can be drawn at the company's option and each maturing in October 2027. An initial $30M tranche was funded at closing with an additional $30M available to be drawn at Replimune's option prior to Sep 30, 2023. An additional $115M tranche will be available upon the company's achievement of specified performance milestones relating to clinical, regulatory, and commercial events. The final $25M tranche is available for draw, at Replimune's (REPL) option and subject to Hercules consent during the interest-only period. The funding provides Replimune (REPL) with significant flexibility as it prepares for key RP1 skin franchise data catalysts and related commercial preparations of its novel tumor-directed oncolytic immunotherapies as well as the advancement of RP2/3 into Phase 2 studies.Seeking Alpha • Aug 12
Replimune: Recent Developments Strengthen Bull Thesis
Shares have lost half of their value since my March 2021 update. Currently, in ROTY we own 8% portfolio weighting with 20% gain. Key pivotal readouts are coming up year end (anti PD-1 failed melanoma) and Q1 2023 (CERPASS CSCC). Recent developments strengthen bullish thesis, including disappointing data from competitor Iovance and Regeneron acquiring Libtayo rights. Updated snapshot of melanoma data (and other skin cancers) shows ORR improving over time. I view opportunity in other solid tumors as a call option. REPL is a Buy. I suggest accumulating dips in the near term. Key risks include disappointing pivotal readouts, setbacks in clinic with RP2/RP3 and difficulties in expanding to other tumor types. This article was originally published for ROTY subscribers on June 9th but has been updated where necessary. Shares of oncolytic immunotherapy pioneer Replimune Group (REPL) have lost roughly half their value since my March 2021 ROTY update was published. In August, I sold our position after key catalysts were pushed out to late 2022. Recently, this one came back to mind after competitor Iovance's (IOVA) disappointing data update in advanced melanoma (shares shed half its market cap). 29% ORR (objective response rate) is still promising but down from the prior number of 35%. Also, keep in mind due to very complicated manufacturing process, TILs (tumor infiltrating lymphocytes) will be quite expensive. Replimune's oncolytic immunotherapy candidate RP1, on the other hand, has potential advantages including "off the shelf" manufacturing, low COGS, and stimulates both adaptive and innate immunity with an attractive safety profile so far. Importantly, in their most recent data update for melanoma, we see the opposite of Iovance with ORR going up over time (now at 37.5% response rate in PD-1 failed melanoma). Corporate Slides Figure 1: Strong anti-PD1 failed melanoma signal for RP1 (Source: corporate slides) Additionally, as I point out in the upcoming edition of ROTY, Regeneron's (REGN) purchase of PD-1 inhibitor Libtayo rights for $900M upfront payment from Sanofi (SNY) signal that the company intends to aggressively expand its oncology business (hat tip to ROTY member dombiotech). This follows a 335% premium for April's buyout of Checkmate Pharmaceuticals (CMPI) to gain rights to vidutolimod (stimulates TLR and is also given via injection into tumor). Pembrolizumab combination in phase 1b study achieved 23.5% ORR in PD-1 failed melanoma. It's not a stretch to think that Replimune could also be in Regeneron's sights to acquire and build out its skin cancer franchise. Given the recent developments above, I'm looking forward to bringing this story back to the attention of the readers. FinViz Figure 2: REPL weekly chart (Source: Finviz) When looking at charts, clarity often comes from taking a look at distinct time frames in order to determine important technical levels and get a feel for what's going on. In the weekly chart above, we can see shares on a steadily decline over much of the past year, which certainly wasn't aided when key data milestones were pushed out until 2022. More recently in the March to June period, shares have bounced around in the low teens to $20 range. My initial take is that dips to low teens are an ideal spot to accumulate a pilot position ahead of the aforementioned melanoma readout later this year, especially in light of Iovance's declining ORR in its pivotal readout. Overview In my March 2021 update, I touched on the following keys to my bullish thesis: Management team appeared highly experienced- back in 2011, they sold BioVex to Amgen (AMGN) ($425 million upfront, $575 million in development in sales milestones). The key asset acquired was the genetically modified oncolytic viral therapy marketed as Imylgic (also known as T-VEC), which was approved in 2015 by both the FDA and EMA. Replimune co-founder and CEO Robert Coffin essentially invented all BioVex products including T-VEC and oversaw all clinical development through dual pivotal phase 3 trials. This time around, leadership's goal was to build on prior success to maximize effectiveness of oncolytic immunotherapy by exploring various initiatives, such as loading multiple immune stimulating genes and extending utility to other solid tumor types. I noted that the company's immulytic platform incorporates a proprietary strain of herpes simplex virus armed with a fusogenic protein enhancing its ability to kill cancer cells and delivering immune stimulating proteins directly to tumors. A logical approach was being taken, first going after "easier" indications in order to gain regulatory approval. For example, the RP-1 clinical strategy involves the so-called rapid path to approval, namely going after tumor types that are already known to be sensitive to anti-PD1 agents. This would be followed up with increasingly more challenging tumor types in a stair-step, incremental fashion. I noted that while there's still substantial risk involved, if management could pull off becoming a universal combination agent for anti-PD1/L1 drugs, patients and shareholders would stand to benefit. Corporate Slides Figure 3: Advantages compared to competitor approaches (Source: corporate slides) Playing devil's advocate, I admitted that in the crowded immuno-oncology field several approaches are being tried out to make immune checkpoint blockade effective for most cancer patients (currently best responses are only in patients with pre-existing immune response and inflamed tumors). While I was initially skeptical considering many companies out there are claiming to "turn cold tumors hot," prior evidence already existed showing the company's unique approach has synergies with checkpoint inhibitors such as ipilimumab. For the indication of cutaneous squamous cell carcinoma or CSCC alone, I noted that four thousand to nine thousand deaths occur annually in the US and it's expected to overtake melanoma as the most lethal skin cancer. While Regeneron's cemiplimab has shown activity (46% response rate), that unfortunately comes with low rate of complete responses. The indication also seemed ideal in that the majority of tumors are accessible for direct injection and there is substantial unmet need here. For Replimune's registrational study in CSCC, I stated that the bar to beat is Libtayo's ORR in CSCC as a single agent (47.2%), which I believe seems readily achievable with the RP1 Libtayo combination. CR rate for Libtayo is just 13% (locally advanced disease) to 20% (metastatic), so again pivotal trial goal of greater than 15% delta improvement in ORR and 2x to 3x improvement in CR rate seemed quite feasible. Corporate Slides Figure 4: High rates of complete responses in prior trial for RP1 (Source: corporate slides) Far from clinical progress being limited to just RP1, I noted that additional efforts including intratumoral anti-CTLA-4 and co-stimulatory pathway agonists were set to enter the clinic in the near to medium term (RP2 and RP3). The former could be interesting as it could overcome a key obstacle (reducing toxicity) and potentially improve activity as compared to current combination of anti-PD1/anti-CTLA-4. To be fair, with suboptimal data so far for RP3 it's always possible it gets discontinued in the near term. Corporate Slides Figure 5: Initial signs of activity for RP2 in traditionally "cold" tumor types (Source: corporate slides) Let's move on to March's Investor Day Presentation to better determine how the story is progressing (lasts 3 hours, you've been warmed). Nuggets from Investor Day Presentation Data for RP1 in melanoma in prior June cut off were already quite mature. Thus, changes observed with newer March cut off have been more modest in scale. Still, it's promising that they've observed further uplift in overall response rate (increased in PD-1 failed cutaneous melanoma to 37.5% from initial 31.3% originally seen). For mucosal melanoma they saw a prior partial response deepen and convert to complete remission of disease. Spaghetti or spider plot shows encouraging depth and durability of response. Very durable treatment benefit is being observed in PD-1 failed cutaneous melanoma. In fact, outcomes appear to be similar whether or not patient has had prior PD-1 therapy. Highlighted patient (blue arrow) had durable stable disease on single agent PD-1 then was re-initiated on RP1 and entered partial response. Corporate Slides Figure 6: Strong PD-1 failed melanoma signal with general deepening of responses over time (Source: corporate slides) As for plans for registration directed study and opportunity here, consider that there are over 7,000 US deaths annually and around half of patients are refractory to anti-PD1 monotherapy, PD-1/CTLA-4 combo or will ultimately progress on this treatment. Response rate to further immune challenge (single agent anti-PD1) is around 7% and there are not yet approved therapies for this setting. Replimune has ongoing registration-directed single arm phase 2 study in 125 patients with anti-PD1 failed cutaneous melanoma. Interim data is expected at the end of 2022. As for NSMC (non-melanoma skin cancers), refer to figure 4 above. As with the melanoma data, we see incremental improvement in response rates. CSCC is particularly of interest given ongoing registrational CERPASS study. CSCC overall response rate increased from 60% to 64.7%. Very high rate of complete remissions was maintained at 47.1%. The activity continues to be observed in other skin cancers (basal cell carcinoma, merkel cell and angiosarcoma). This highlights the potential of RP1 across a broad range of tumor types (skin cancer franchise). CERPASS randomized phase 2 study in CSCC (RP1 cemiplimab combo versus cemiplimab alone) has dual independent primary endpoints of overall response rate and complete remission rate. Enrollment will be completed midyear with topline data available at beginning of 2023. As for first look at RP1 Opdivo combo in PD1-failed NMSC, number of patients is small but initial data is promising (responses in CSCC, MCC and angiosarcomas with all of responding patients in maintained response to date). Overall response rate for this group on the whole is 1 in 3 or 33% and number of other patients not on study for long are in stable disease (anticipate that some of these may evolve into further responses). In the first 6 patients (solid organ transplant recipients) they have achieved one PR, one CR, one responding patient died from Covid before benefit could be assessed. Covid has significantly impacted recruitment to trial, but now it is picking up as pandemic is waning. 1/3rd of patients had response, promising but early in nature. The company is entering a critical 12 months as they prepare on the commercial side for initial launches. The first goal is to rapidly establish RP1 in CSCC (could provide better 1st line/neoadjuvant therapy as well as better 2nd line therapy post CPI). Second launch will be in PD-1 failed melanoma to continue the momentum and build meaningful skin franchise. They can then move into other skin cancers (MCC, angiosarcoma, etc). Across all segments you are looking at a US population of around 40,000 patients. As for skeptics asking why they are different to predecessor T-Vec, management states that T-Vec was great proof of concept but did not launch with strong data or label. Replimune aims to come to market with compelling value proposition and strong data set (a more potent oncolytic immunotherapy platform drives stronger systemic immune response). RP1 can be used in combination of standard of care (not replacing IO). Beyond skin cancers, the second step to pursue is to make intratumoral injections into tumors a routine part of care (inject in deeper areas such as visceral lymph nodes and metastases). This includes indications where delivery is part of routine medical practice (ie. liver cancer or metastases where use of repeat ultrasound and injections into liver already occurs). They are "swimming with the tide" in these indications versus against it. Corporate Slides Figure 7: Indication prioritization via means of administration (Source: corporate slides) HCC, RCC, head and neck are areas of unmet need and also represent indications where they can more easily do deep injections. Liver mets jumps out as a key commercial opportunity here (tumor microenvironment here is a real issue for existing IO treatments). Proof of concept data in late line patients will allow them to rapidly move into larger opportunities in earlier disease. RP2 nivolumab combo data in 30 patient phase one study resulted in 7 responses, all of whom failed prior anti PD-1 therapy (2 uveal melanoma, 4 cutaneous melanoma, 1 SCCHN). RP3 was well tolerated so far, but there was little sign of efficacy in these later line patients (devil's advocate, consider it to be a zero). Other Information For the second quarter of 2022, the company reported cash and equivalents of $395M comparing favorably to net loss of $42.3M. R&D expenses rose to $29.5M, while SG&A rose to $11.4M. Management is guiding for cash runway into the second half of 2024. Accumulated deficit since inception in 2015 is $311.2M per latest 10-K filing. As for prior financings, in October of 2020 the company sold roughly 4.7 million common shares at $40/share for gross proceeds of $40/share, in addition to pre-funded warrants to purchase 1.56M common shares at $39.99/share (represents more than a double from current levels). Again, the two main catalysts that come to mind are PD-1 failed melanoma data by year end 2022 and pivotal CSCC results in early 2022. For CSCC, cemiplimab was approved in 2018 followed by pembrolizumab in 2020 (ORR ~35-45%, CRR~ 5-15%). Pivotal trial for RP1 combo has dual primary endpoint of CRR (complete response rate) and ORR (15% absolute difference required). For pivotal PD-1 failed melanoma trial, primary endpoint is ORR and I would think 30% or more would be quite good when looking at Iovance's data (mid to high 30's even better). Again, a second-line of anti-PD1 therapy achieves mid to high single digit ORR at best. Data for RP2 and RP3 later in the year will determine which candidate moves forward to phase 2 studies.분석 기사 • Aug 06
Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Aug 04
Replimune Group GAAP EPS of -$0.78 misses by $0.15
Replimune Group press release (NASDAQ:REPL): FQ1 GAAP EPS of -$0.78 misses by $0.15. As of June 30, 2022, cash, cash equivalents and short-term investments were $395.1 million. Shares -4.98% PM.분석 기사 • Jun 24
Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 23% Below Their Intrinsic Value Estimate
In this article we are going to estimate the intrinsic value of Replimune Group, Inc. ( NASDAQ:REPL ) by estimating the...분석 기사 • Apr 04
We're Not Very Worried About Replimune Group's (NASDAQ:REPL) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...분석 기사 • Dec 16
Companies Like Replimune Group (NASDAQ:REPL) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...매출 및 비용 세부 내역
매출 및 비용 세부 내역
Replimune Group가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.
순이익 및 매출 추이
| 날짜 | 매출 | 순이익 | 일반관리비 | 연구개발비 |
|---|---|---|---|---|
| 31 Dec 25 | 0 | -315 | 104 | 220 |
| 30 Sep 25 | 0 | -310 | 102 | 216 |
| 30 Jun 25 | 0 | -280 | 91 | 202 |
| 31 Mar 25 | 0 | -247 | 73 | 187 |
| 31 Dec 24 | 0 | -228 | 64 | 175 |
| 30 Sep 24 | 0 | -213 | 61 | 169 |
| 30 Jun 24 | 0 | -220 | 60 | 175 |
| 31 Mar 24 | 0 | -216 | 61 | 172 |
| 31 Dec 23 | 0 | -210 | 59 | 167 |
| 30 Sep 23 | 0 | -199 | 57 | 155 |
| 30 Jun 23 | 0 | -182 | 55 | 134 |
| 31 Mar 23 | 0 | -174 | 51 | 123 |
| 31 Dec 22 | 0 | -157 | 46 | 107 |
| 30 Sep 22 | 0 | -147 | 45 | 96 |
| 30 Jun 22 | 0 | -133 | 42 | 87 |
| 31 Mar 22 | 0 | -118 | 39 | 76 |
| 31 Dec 21 | 0 | -108 | 35 | 71 |
| 30 Sep 21 | 0 | -100 | 31 | 66 |
| 30 Jun 21 | 0 | -91 | 27 | 60 |
| 31 Mar 21 | 0 | -81 | 24 | 54 |
| 31 Dec 20 | 0 | -75 | 23 | 48 |
| 30 Sep 20 | 0 | -70 | 21 | 46 |
| 30 Jun 20 | 0 | -61 | 20 | 40 |
| 31 Mar 20 | 0 | -53 | 17 | 36 |
| 31 Dec 19 | 0 | -43 | 15 | 30 |
| 30 Sep 19 | 0 | -35 | 12 | 25 |
| 30 Jun 19 | 0 | -30 | 10 | 23 |
| 31 Mar 19 | 0 | -31 | 9 | 20 |
| 31 Dec 18 | 0 | -31 | 9 | 19 |
| 30 Sep 18 | 0 | -28 | 8 | 15 |
| 30 Jun 18 | 0 | -26 | 7 | 13 |
| 31 Mar 18 | 0 | -20 | 6 | 11 |
| 31 Dec 17 | 0 | -17 | 4 | 9 |
양질의 수익: REPL 은(는) 현재 수익성이 없습니다.
이익 마진 증가: REPL는 현재 수익성이 없습니다.
잉여현금흐름 대비 순이익 분석
과거 순이익 성장 분석
수익추이: REPL은 수익성이 없으며 지난 5년 동안 손실이 연평균 25.5% 증가했습니다.
성장 가속화: 현재 수익성이 없어 지난 1년간 REPL의 수익 성장률을 5년 평균과 비교할 수 없습니다.
수익 대 산업: REPL은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(31.5%)와 비교하기 어렵습니다.
자기자본이익률
높은 ROE: REPL는 현재 수익성이 없으므로 자본 수익률이 음수(-149.55%)입니다.
총자산이익률
투하자본수익률
우수한 과거 실적 기업을 찾아보세요
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/07 04:24 |
| 종가 | 2026/05/06 00:00 |
| 수익 | 2025/12/31 |
| 연간 수익 | 2025/03/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Replimune Group, Inc.는 13명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Clarence Powell | BMO Capital Markets Equity Research |
| Evan Seigerman | BMO Capital Markets Equity Research |
| Guyn Kim | BMO Capital Markets Equity Research |